US Patent

US7994220 — Milnacipran for the long-term treatment of fibromyalgia syndrome

Method of Use · Assigned to Cypress Bioscience Inc · Expires 2029-09-19 · 3y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for the long-term treatment of fibromyalgia syndrome using a norepinephrine-serotonin reuptake inhibitor.

USPTO Abstract

The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering a norepinephrine-serotonin reuptake inhibitor (NSRI) to a patient with FMS.

Drugs covered by this patent

milnacipran-hydrochloride (MILNACIPRAN HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-819`	—	milnacipran-hydrochloride
`U-819`	—	milnacipran-hydrochloride
`U-819`	—	milnacipran-hydrochloride
`U-819`	—	milnacipran-hydrochloride

Patent Metadata

Patent number: US7994220
Jurisdiction: US
Classification: Method of Use
Expires: 2029-09-19
Drug substance claim: No
Drug product claim: No
Assignee: Cypress Bioscience Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.